CA2106105A1 - Compositions d'addition oxyde nitrique-agent polymerique liees par des polymeres, compositions pharmaceutiques incorporant ces produits et methodes pour le traitement de desordresbiologiques a l'aide de ceux-ci - Google Patents

Compositions d'addition oxyde nitrique-agent polymerique liees par des polymeres, compositions pharmaceutiques incorporant ces produits et methodes pour le traitement de desordresbiologiques a l'aide de ceux-ci

Info

Publication number
CA2106105A1
CA2106105A1 CA002106105A CA2106105A CA2106105A1 CA 2106105 A1 CA2106105 A1 CA 2106105A1 CA 002106105 A CA002106105 A CA 002106105A CA 2106105 A CA2106105 A CA 2106105A CA 2106105 A1 CA2106105 A1 CA 2106105A1
Authority
CA
Canada
Prior art keywords
same
nitric oxide
polymer
methods
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002106105A
Other languages
English (en)
Other versions
CA2106105C (fr
Inventor
Larry K. Keefer
Joseph A. Hrabie
Joseph E. Saavedra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to CA002106105A priority Critical patent/CA2106105C/fr
Publication of CA2106105A1 publication Critical patent/CA2106105A1/fr
Application granted granted Critical
Publication of CA2106105C publication Critical patent/CA2106105C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
    • C08F8/32—Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F112/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
    • C08F112/02—Monomers containing only one unsaturated aliphatic radical
    • C08F112/04—Monomers containing only one unsaturated aliphatic radical containing one ring
    • C08F112/14—Monomers containing only one unsaturated aliphatic radical containing one ring substituted by hetero atoms or groups containing heteroatoms
    • C08F112/16—Halogens
    • C08F112/18—Chlorine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
CA002106105A 1993-09-14 1993-09-14 Compositions d'addition oxyde nitrique-agent polymerique liees par des polymeres, compositions pharmaceutiques incorporant ces produits et methodes pour le traitement de desordresbiologiques a l'aide de ceux-ci Expired - Fee Related CA2106105C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002106105A CA2106105C (fr) 1993-09-14 1993-09-14 Compositions d'addition oxyde nitrique-agent polymerique liees par des polymeres, compositions pharmaceutiques incorporant ces produits et methodes pour le traitement de desordresbiologiques a l'aide de ceux-ci

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002106105A CA2106105C (fr) 1993-09-14 1993-09-14 Compositions d'addition oxyde nitrique-agent polymerique liees par des polymeres, compositions pharmaceutiques incorporant ces produits et methodes pour le traitement de desordresbiologiques a l'aide de ceux-ci

Publications (2)

Publication Number Publication Date
CA2106105A1 true CA2106105A1 (fr) 1995-03-15
CA2106105C CA2106105C (fr) 2008-03-18

Family

ID=4152307

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002106105A Expired - Fee Related CA2106105C (fr) 1993-09-14 1993-09-14 Compositions d'addition oxyde nitrique-agent polymerique liees par des polymeres, compositions pharmaceutiques incorporant ces produits et methodes pour le traitement de desordresbiologiques a l'aide de ceux-ci

Country Status (1)

Country Link
CA (1) CA2106105C (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015781A1 (fr) * 1994-11-22 1996-05-30 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Utilisation d'agents liberant de l'oxyde nitrique pour reduire les risques de metastase
WO1996016645A1 (fr) * 1994-11-25 1996-06-06 The Wellcome Foundation Limited Utilisation de donneurs d'oxyde nitrique dans le domaine medical
EP0724436A1 (fr) * 1993-09-17 1996-08-07 Brigham And Women's Hospital Produits d'addition de l'oxyde nitrique utilises dans la prevention de la thrombose sur des surfaces artificielles et vasculaires
WO1996032118A1 (fr) * 1995-04-10 1996-10-17 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Utilisation d'agents degageant de l'oxyde nitrique pour traiter l'impuissance
JPH11503456A (ja) * 1995-04-10 1999-03-26 アメリカ合衆国 多糖結合ニトリックオキサイド−求核剤付加物
US6174539B1 (en) 1993-09-17 2001-01-16 Nitromed, Inc. Localized use of nitric oxide adducts to prevent internal tissue damage
US6255277B1 (en) 1993-09-17 2001-07-03 Brigham And Women's Hospital Localized use of nitric oxide-adducts to prevent internal tissue damage
EP0914348B1 (fr) * 1996-08-02 2002-06-12 Duke University Medical Center Polymeres destines a apporter du monoxyde d'azote in vivo
EP1690532A1 (fr) * 2005-02-11 2006-08-16 NOLabs AB Dispositif pour traitement gastrique et son procédé de fabrication
WO2006084914A2 (fr) * 2005-02-11 2006-08-17 Nolabs Ab Dispositif de traitement gastrique, procede de fabrication associe et utilisation d'oxyde nitrique
CN106574005A (zh) * 2014-08-14 2017-04-19 罗门哈斯公司 具有可释放气体的聚合物

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US6290981B1 (en) 1992-08-24 2001-09-18 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US6352709B1 (en) 1993-09-17 2002-03-05 Nitromed, Inc. Localized use of nitric oxide-adducts to prevent internal tissue damage
EP0724436A1 (fr) * 1993-09-17 1996-08-07 Brigham And Women's Hospital Produits d'addition de l'oxyde nitrique utilises dans la prevention de la thrombose sur des surfaces artificielles et vasculaires
EP0724436A4 (fr) * 1993-09-17 1999-09-01 Brigham & Womens Hospital Produits d'addition de l'oxyde nitrique utilises dans la prevention de la thrombose sur des surfaces artificielles et vasculaires
US6174539B1 (en) 1993-09-17 2001-01-16 Nitromed, Inc. Localized use of nitric oxide adducts to prevent internal tissue damage
US6255277B1 (en) 1993-09-17 2001-07-03 Brigham And Women's Hospital Localized use of nitric oxide-adducts to prevent internal tissue damage
US6471978B1 (en) 1993-09-17 2002-10-29 Brigham And Women's Hospital Localized use of nitric oxide-adducts to prevent internal tissue damage
EP1393723A2 (fr) * 1993-09-17 2004-03-03 Brigham & Women's Hospital Utilisation d'adduits de monoxyde d'azote pour la prévention des thromboses sur des surfaces artificielles ou vasculaires
EP1393723A3 (fr) * 1993-09-17 2004-10-20 The Brigham And Women's Hospital, Inc. Utilisation d'adduits de monoxyde d'azote pour la prévention des thromboses sur des surfaces artificielles ou vasculaires
WO1996015781A1 (fr) * 1994-11-22 1996-05-30 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Utilisation d'agents liberant de l'oxyde nitrique pour reduire les risques de metastase
WO1996016645A1 (fr) * 1994-11-25 1996-06-06 The Wellcome Foundation Limited Utilisation de donneurs d'oxyde nitrique dans le domaine medical
JP2010111675A (ja) * 1995-04-10 2010-05-20 Usa Government 多糖結合ニトリックオキサイド−求核剤付加物
JPH11503456A (ja) * 1995-04-10 1999-03-26 アメリカ合衆国 多糖結合ニトリックオキサイド−求核剤付加物
WO1996032118A1 (fr) * 1995-04-10 1996-10-17 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Utilisation d'agents degageant de l'oxyde nitrique pour traiter l'impuissance
EP0914348B1 (fr) * 1996-08-02 2002-06-12 Duke University Medical Center Polymeres destines a apporter du monoxyde d'azote in vivo
WO2006084914A2 (fr) * 2005-02-11 2006-08-17 Nolabs Ab Dispositif de traitement gastrique, procede de fabrication associe et utilisation d'oxyde nitrique
WO2006084914A3 (fr) * 2005-02-11 2006-11-16 Nolabs Ab Dispositif de traitement gastrique, procede de fabrication associe et utilisation d'oxyde nitrique
EP1690532A1 (fr) * 2005-02-11 2006-08-16 NOLabs AB Dispositif pour traitement gastrique et son procédé de fabrication
CN106574005A (zh) * 2014-08-14 2017-04-19 罗门哈斯公司 具有可释放气体的聚合物

Also Published As

Publication number Publication date
CA2106105C (fr) 2008-03-18

Similar Documents

Publication Publication Date Title
CA2216696A1 (fr) Produits d'addition bioxyde d'azote-nucleophiles lies a des polysaccharides
CA1087984A (fr) Antibiotique contenant des acides amines dans une base de resine synthetique
CA2131830A1 (fr) Article d'orthodontie interocclusal, mou et flexible; methode d'obtention et composition pour le preparer
CA2106105A1 (fr) Compositions d'addition oxyde nitrique-agent polymerique liees par des polymeres, compositions pharmaceutiques incorporant ces produits et methodes pour le traitement de desordresbiologiques a l'aide de ceux-ci
CA2132293A1 (fr) Dispositif medical a desintegration provoquee
CA2158638A1 (fr) Composition et methode d'augmentation tissulaire
EP0627899A4 (fr) Compositions ceramiques injectables et leur procede de preparation et d'utilisation.
DE69432025D1 (de) Formulierungen mit verzögerter freisetzung zur abgabe von metoprolol über 24 stunden
DE2706135A1 (de) Verdickungsmittel fuer ausgeschiedenen darminhalt und harn
CA2310222A1 (fr) Nouvelle composition de matiere
WO1998027963A3 (fr) Procedes et composition a base de gel
BR9710984A (pt) Uso de um polìmero, homopolìmero ou copolìmero na obtenção de um medicamento para tratar uma infecção gastrointestinal ou microbiana em um mamìfero
DE10114247A1 (de) Antibiotikum-/Antibiotika-Polymer-Kombination
CA2128044A1 (fr) Compositions pharmaceutiques comportant un glucosidase et/ou un inhibiteur d'amylase, et un inhibiteur des lipases
AU1351788A (en) Slow-release pharmaceutical agent
GB2197329B (en) Hard tissue substitute composition
PT93384A (pt) Processo para a preparacao de um material de revestimento de controlo da libertacao de droga para formulacoes de accao prolongada contendo copolimeros de (met)acrilato
GB2028662A (en) Covering material
CA2157323A1 (fr) Forme posologique de la gepirone
WO1998022097A3 (fr) Composition d'une matrice a liberation controlee utilisant un melange d'acide poly(acrylique) et d'un polymere ou d'un monomere polaire
CA2067381A1 (fr) Traitement des infections a vih et composes utiles a cet egard
CA2159730A1 (fr) Polymeres d'ionene, agents vermifuges pour animaux
CA2189436A1 (fr) Composition d'hygiene buccale
WO1999061014A3 (fr) Compositions et methodes utilisant de la r(-) fluoxetine et d'autres ingredients actifs
EP1648531B1 (fr) Utilisation de principes actifs antiseptiques dans des ciments osseux en pmma

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed